Novo Nordisk is losing market share despite its having a "comprehensive portfolio" compared to peers, the firm said.
Get this delivered to your inbox, and more info about our products and services.
TD Cowen still sees shares of Novo Nordisk adding 6% from here.
The bank downgraded the Danish pharmaceutical giant to neutral from buy and decreased its price target.
Despite being first to launch a GLP-1 drug for weight loss, Novo's market share has eroded, and the company now only captures…
The Wegovy obesity drug maker on Wednesday announced plans to trim 11.5% of its workforce.
The company is banking on its Wegovy pill and next-generation weight loss injectable CagriSema to recapture share of the key U.S.…
Charlotte Reed speaks with Mike Doustdar, CEO of Novo Nordisk, after the Danish comapny hiked its 2026 full-year guidance on the…
